Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries

Journal of Vascular Surgery

Volumn 44, Issue 4, 2006, Pages 776-781

  Hackam, Daniel G ^a   Tan, Mary K ^a   Lin, Peter J ^a,b   Mehta, Pravinsagar G ^c   Jaffer, Shahin ^d   Kates, Martin ^e   Oh, Mona ^a   Grima, Etienne A ^a   Langer, Anatoly ^a,f   Goodman, Shaun G ^a,f  

^a CANADIAN HEART RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Delta Hospital   (Canada)

^e St Michael's Hospital ^*

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CANADA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIAL OCCLUSIVE DISEASES; CANADA; CEREBROVASCULAR DISORDERS; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SURVIVAL RATE;

EID: 33749028169     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.05.057     Document Type: Article

References (29)

1. Belch J.J., Topol E.J., Agnelli G., Bertrand M., Califf R.M., Clement D.L., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003) 884-892
2. Leng G.C., Lee A.J., Fowkes F.G., Whiteman M., Dunbar J., Housley E., et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25 (1996) 1172-1181
3. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
4. Hankey G.J., Norman P.E., and Eikelboom J.W. Medical treatment of peripheral arterial disease. JAMA 295 (2006) 547-553
5. Feringa H.H.H., van Waning V.H., Bax J.J., Elhendy A., Boersma E., Schouten O., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 (2006) 1182-1187
6. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)-endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-e654
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27 Suppl 2 (2003) S58-S65
8. Alpert J.S. Are data from clinical registries of any value?. Eur Heart J 21 (2000) 1399-1401
9. Zeymer U., and Senges J. Why do we need prospective registries in patients with acute myocardial infarction?. Eur Heart J 24 (2003) 1611-1612
10. McDermott M.M., Greenland P., Green D., Guralnik J.M., Criqui M.H., Liu K., et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 107 (2003) 3191-3198
11. McDermott M.M., Green D., Greenland P., Liu K., Criqui M.H., Chan C., et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 92 (2003) 194-199
12. Smith F.B., Rumley A., Lee A.J., Leng G.C., Fowkes F.G., and Lowe G.D. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 100 (1998) 758-763
13. Smith F.B., Lee A.J., Hau C.M., Rumley A., Lowe G.D., and Fowkes F.G. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 11 (2000) 43-50
14. Narins C.R., Zareba W., Moss A.J., Marder V.J., Ridker P.M., Krone R.J., et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 164 (2004) 440-446
15. Killewich L.A., Gardner A.W., Macko R.F., Hanna D.J., Goldberg A.P., Cox D.K., et al. Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 27 (1998) 645-650
16. Komarov A., Panchenko E., Dobrovolsky A., Karpov Y., Deev A., Titaeva E., et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 23 (2002) 1309-1316
17. Cassar K., Bachoo P., Ford I., Greaves M., and Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 38 (2003) 99-103
18. Robless P.A., Okonko D., Lintott P., Mansfield A.O., Mikhailidis D.P., and Stansby G.P. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25 (2003) 16-22
19. Schillinger M.M., Exner M.M., Amighi J.M., Mlekusch W.M., Sabeti S.M., Rumpold H.M., et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 108 (2003) 2323-2328
20. Brevetti G., Piscione F., Silvestro A., Galasso G., Di Donato A., Oliva G., et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 89 (2003) 1058-1063
21. Nicoloff A.D., Taylor Jr. L.M., Sexton G.J., Schuff R.A., Edwards J.M., Yeager R.A., et al. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg 35 (2002) 38-46
22. Aronow W.S., and Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol 74 (1994) 64-65
23. Henke P.K., Blackburn S., Proctor M.C., Stevens J., Mukherjee D., Rajagopalin S., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39 (2004) 357-365
24. Hirsch A.T., and Gotto Jr. A.M. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. Vasc Med 7 (2002) 323-331
25. Cambou J.P., Ferrieres J., Grenier O., Boka G., Cantet C., and Leizorovicz A. Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey. Ann Cardiol Angeiol (Paris) 52 (2003) 20-29
26. Hooi J.D., Kester A.D., Stoffers H.E., Rinkens P.E., Knottnerus J.A., and van Ree J.W. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 57 (2004) 294-300
27. Nikolsky E., Mehran R., Mintz G.S., Dangas G.D., Lansky A.J., Aymong E.D., et al. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. J Endovasc Ther 11 (2004) 60-70
28. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
29. Mehler P.S., Coll J.R., Estacio R., Esler A., Schrier R.W., and Hiatt W.R. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 107 (2003) 753-756